GOVX

Company Overview — What Does GeoVax Labs, Inc. Do?

GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; Centers for Disease Control and Prevention; U.S. Department of Defense; Emory University; University of Pittsburgh; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is based in Smyrna, Georgia. GeoVax Labs, Inc. (GOVX) is classified as a micro-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO David A. Dodd and employs approximately 10 people. With a market capitalization of $3M, GOVX is one of the notable companies in the Healthcare sector.

GeoVax Labs, Inc. (GOVX) Stock Rating — Reduce (April 2026)

As of April 2026, GeoVax Labs, Inc. receives a Reduce rating with a composite score of 28.7/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.GOVX ranks #3,621 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, GeoVax Labs, Inc. ranks #585 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

GOVX Stock Price and 52-Week Range

GeoVax Labs, Inc. (GOVX) currently trades at $1.15. The stock lost $0.01 (0.9%) in the most recent trading session. The 52-week high for GOVX is $4.40, which means the stock is currently trading -73.9% from its annual peak. The 52-week low is $0.12, putting the stock 899.1% above its annual trough. Recent trading volume was 83K shares, suggesting relatively thin trading activity.

Is GOVX Overvalued or Undervalued? — Valuation Analysis

GeoVax Labs, Inc. (GOVX) carries a value factor score of 8/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 0.55x, versus the sector average of 2.75x. The price-to-sales ratio is 0.51x, compared to 1.66x for the average Healthcare stock.

At current multiples, GeoVax Labs, Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

GeoVax Labs, Inc. Profitability — ROE, Margins, and Quality Score

GeoVax Labs, Inc. (GOVX) earns a quality factor score of 10/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -465.9%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -339.6% versus the sector average of -33.1%.

The operating margin is -392.0% (sector: -66.1%). Net profit margin stands at -388.6%, versus -58.7% for the average Healthcare stock. Revenue growth is running at -100.0% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

GOVX Debt, Balance Sheet, and Financial Health

GeoVax Labs, Inc. has a debt-to-equity ratio of 37.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 3.57x, indicating strong short-term liquidity. Total debt on the balance sheet is $0. Cash and equivalents stand at $5M.

GOVX has a beta of 2.21, meaning it is more volatile than the broader market — a $10,000 investment in GOVX would be expected to move 121.2% more than the S&P 500 on any given day. The stability factor score for GeoVax Labs, Inc. is 7/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

GeoVax Labs, Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, GeoVax Labs, Inc. reported revenue of $5M and earnings per share (EPS) of $-0.31. Net income for the quarter was $-23M. Operating income came in at $-23M.

In Q3 2025, GeoVax Labs, Inc. reported revenue of $0 and earnings per share (EPS) of $-0.31. Net income for the quarter was $-6M. Operating income came in at $-6M.

In Q2 2025, GeoVax Labs, Inc. reported revenue of $852,282 and earnings per share (EPS) of $-0.35. Net income for the quarter was $-5M. Revenue grew 183.5% year-over-year compared to Q2 2024. Operating income came in at $-5M.

In Q1 2025, GeoVax Labs, Inc. reported revenue of $2M and earnings per share (EPS) of $-0.45. Net income for the quarter was $-5M. Operating income came in at $-5M.

Over the past 8 quarters, GeoVax Labs, Inc. has demonstrated a growth trajectory, with revenue expanding from $0 to $5M. Investors analyzing GOVX stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

GOVX Dividend Yield and Income Analysis

GeoVax Labs, Inc. (GOVX) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

GOVX Momentum and Technical Analysis Profile

GeoVax Labs, Inc. (GOVX) has a momentum factor score of 64/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 40/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 38/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.

GOVX vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, GeoVax Labs, Inc. (GOVX) ranks #585 out of 838 stocks based on the Blank Capital composite score. This places GOVX in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing GOVX against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full GOVX vs S&P 500 (SPY) comparison to assess how GeoVax Labs, Inc. stacks up against the broader market across all factor dimensions.

GOVX Next Earnings Date

No upcoming earnings date has been announced for GeoVax Labs, Inc. (GOVX) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy GOVX? — Investment Thesis Summary

The quantitative profile for GeoVax Labs, Inc. suggests caution. The quality score of 10/100 flags below-average profitability. The value score of 8/100 indicates premium valuation. Price momentum is positive at 64/100, suggesting the trend favors buyers. High volatility (stability score 7/100) increases portfolio risk.

In summary, GeoVax Labs, Inc. (GOVX) earns a Reduce rating with a composite score of 28.7/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on GOVX stock.

Related Resources for GOVX Investors

Explore more research and tools: GOVX vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare GOVX head-to-head with peers: GOVX vs AZN, GOVX vs SLGL, GOVX vs VMD.